Central Government Restricts Use of Common Cold Drug Combination in Children Under Four

The Central Government has now mandated that all manufacturers of fixed-dose combinations of Chlorpheniramine Maleate and Phenylephrine Hydrochloride must clearly and prominently mention the warning “fixed dose combination shall not be used in children below four years of age” on the label, package insert, and any promotional literature associated with the drug.

CDSCO Revises Drug Alert List For November 2024 & January 2025

The Central Drugs Standard Control Organisation (CDSCO) has issued drug alerts for specific batches of Tofacitinib Tablets IP 5 mg (marketed as TOFAJAK TABLETS) and TELMA AM, declaring them as potentially spurious following investigations into their quality. Consumers and healthcare providers are advised to stay informed about such alerts issued by regulatory authorities to ensure the safety and efficacy of the medications they use or dispense.

CDSCO Publishes Not Of Standard Quality And Spurious Alert For March 2025

The NSQ drug list specifies a total of 61 drugs that were detected to be deficient by State Lab Drugs Control Laboratories. The NSQ drug list for central CDSCO laboratories specifies a total of 70 drugs that were detected to be deficient. Additionally, CDSCO has also identified 1 drug to be spurious.

Revised Cut-off Timings for AMCs

New Cut-off Timings shall be observed by AMCs with respect to repurchase of units in liquid fund & overnight fund schemes and plans.